CAMBRIDGE, Mass., Aug. 1, 2024
/PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a
clinical-stage immunology company advancing RNA therapeutics to
conquer cancer, announced today its participation in the Barclays
Biotech: 1x1 Private Company Symposium on Wednesday, August 7, 2024.
This event is being held in a virtual format during which
Company management will participate in one-on-one meetings with
investors.
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage immunology
company, engineering cutting-edge RNA technology to program
immune cells to combat cancer and other deadly diseases. Myeloid is
headquartered in Cambridge,
MA.
For additional information, please
visit, https://www.myeloidtx.com/ and follow us
on LinkedIn and X/Twitter. For collaborative
interests, write to partnering@myeloidtx.com.
Investor Contact
Amy Conrad
Juniper Point
Amy@juniper-point.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/myeloid-therapeutics-to-participate-in-barclays-biotech-1x1-private-company-symposium-302212768.html
SOURCE Myeloid Therapeutics